Press Releases

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) for its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The primary objective of the study is to measure the improvement in muscle strength in the lower limbs, as assessed by knee extension test. Secondary endpoints will include analysis of mobility (via the 6-minute walk test) and body composition (assessment of fat and lean mass). A world-renowned medical expert in the field of obesity

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France. Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious Diseases department at Pitié Salpetriere, presented the COVA phase 2/3 clincial study results in a context where the number of Covid cases rises again. Dr. Claudia Ferreira MD, PhD, Medical Director at

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 34% of the shareholders present or represented. The resolutions notably included the approval of the financial statements fo the fiscal year 2023 and the renewal for three years of Stanislas Veillet, Nadine Coulm and Claude Allary as Directors. The results of

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and speciality markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and speciality products, has produced the first GMP-compliant batch of BIO101 (20-hydroxyecdysone) at its plant in Villeneuve La Garenne (Île-de-France). This batch is now available for use in Biophytis’ clinical development programme to treat respiratory deterioration in patients with Duchenne Muscular Dystrophy (DMD). DMD is a rare genetic disease that causes severe and progressive muscle degeneration, mainly affecting boys. BIO101 (20-hydroxyecdysone)

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). Fullscreen Mode

Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université – Amphi Herpin – 4 Place Jussieu, 75005 Paris. The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO) no. 59 of May 15, 2024. Information and preparatory documents for this General Meeting, including the voting form and the access map, are available on the Company’s website. Shareholders are strongly encouraged to vote in advance of the CGM, by (i)

Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight with secondary comorbidities, who are starting treatment with GLP-1 RAs for weight loss. Stanislas Veillet, CEO of Biophytis, stated: “It is crucial for Biophytis to position itself on this gigantic medical challenge which also presents